Clinical Research Directory

Inclusion Criteria: * Patients with high bleeding risk (defined according to the ARC-HBR criteria) who have undergone PCI and are on maintenance treatment with DAPT, consisting of low-dose aspirin (81mg qd) with clopidogrel (75 mg qd) as part of standard of care for at least 30 days. * Age ≥18 years. * Provide written informed consent. Exclusion Criteria: * Prior cerebrovascular event. * PCI within 30 days. * Hemodynamic instability. * On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis). * Hypersensitivity to Aspirin, Clopidogrel, or Prasugrel. * Known hematologic malignancies or thrombocytopenia (platelet count \<80x106/mL). * Known hemoglobinopathies or anemia (hemoglobin \<9 g/dL) * Pregnant and breastfeeding women \[women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\].